A
abdominal CT scan, P-7
abdominal pain, 10-1
acanthosis nigricans, 5-28
accessory pathway, 1-33
acetaminophen
as cause of metabolic acidosis, 4-2
hepatotoxicity, 3-19
achalasia, 3-1
acid-base disturbances, 4-1
acquired immunodeficiency syndrome (AIDS), 6-17
acromegaly, 7-2
activated protein C resistance, 5-11
acute abdomen, 10-1
acute aortic syndrome, 1-31
acute coronary syndromes, 1-6
acute interstitial nephritis, 4-12, 4-13
acute interstitial pneumonia, 2-10
acute kidney injury, 4-12
acute limb ischemia, 1-41
acute respiratory distress syndrome (ARDS), 2-22
acute tubular necrosis, 4-12
Addison’s disease, 7-9
adnexal mass, non-pregnant woman, 10-3
adrenal disorders, 7-7
adrenal incidentalomas, 7-10
adrenal insufficiency, 7-9
adrenal mass, 7-10
advanced cardiac life support, ACLS-1
albuminuria, 4-14
alcohol withdrawal, 9-5
allergic bronchopulmonary aspergillosis, 2-10
alpha1-antitrypsin deficiency
as cause of cirrhosis, 3-24
as cause of COPD, 2-5
alveolar gas equation, 11-6
amaurosis fugax, 9-6
amiodarone, thyroid disease and, 7-6
amyloidosis, 8-22
cardiac manifestations, 1-19
anaphylaxis, 2-4
anaplasmosis, 6-21
anemia, 5-1
aplastic, 5-3
autoimmune hemolytic, 5-5, P-13
of chronic inflammation, 5-2
Cooley’s, 5-2
Fanconi’s, 5-3
folate deficiency, 5-3
hemolytic, 5-4
macrocytic, 5-3
microangiopathic hemolytic, 5-5
microcytic, 5-1
myelophthisic, 5-4
normocytic, 5-2
pernicious, 5-3
sideroblastic, 5-2
angioectasia, 3-3
angioedema, 2-4
angioplasty, 1-5
ankylosing spondylitis, 8-7
anoxic brain injury, 9-2
antibiotics, 11-3
antibodies
anti-centromere, 8-11
anti-cyclic citrullinated peptide (CCP), 8-3
anti-ds-DNA, 8-15
anti-GBM, 4-17
anti-histone, 8-15
anti-Jo-1, 8-13
anti-Mi-2, 8-13
antimitochondrial, 3-24
antineutrophil cytoplasmic (ANCA), 4-17, 8-18
antiphospholipid, 5-11
anti-Scl-70, 8-11
anti-Sm, 8-15
anti-smooth muscle, 3-19
anti-SRP, 8-13
autoantibodies, 8-2
in connective tissue diseases, 8-11
anti-GBM disease, as cause of glomerulonephritis, 4-17
antiphospholipid syndrome, 5-11
aortic aneurysm, 1-30
aortic dissection, 1-31
aortic regurgitation, 1-21
aortic stenosis, 1-20
aortoenteric fistula, 3-4
arrhythmias, 1-32
arthralgias, 8-1
arthritis, 8-1
IBD-associated (enteropathic), 8-7
infectious, 8-9
osteoarthritis, 8-1
psoriatic, 8-7
reactive, 8-7
rheumatoid, 8-3
asbestosis, 2-10
ascites, 3-26
treatment of, in cirrhotics, 3-21
aspergillosis, 6-4
asplenia, 6-4
asthma, 2-2
atrial fibrillation, 1-32, 1-35
Auer rod, 5-17
autoimmune polyglandular syndromes (APS), 7-2
auto-PEEP, 2-20
AV block, 1-32
AV dissociation, 1-32
B
babesiosis, 6-21
bacillary angiomatosis, 6-18
back pain, 9-11
bacteremia, 6-12
Barrett’s esophagus, 3-2
Bartter’s syndrome, 4-5, 4-10, 7-8
basophilia, 5-12
basophilic stippling, 5-2, 11-8
Beck’s triad, 1-26
Behçet’s syndrome, 8-20
Bell’s palsy, 6-11
Bernard-Soulier disease, 5-9
berylliosis, 2-10
bilevel positive airway pressure (BiPAP), 2-19
biliary tract disease, 3-27
biventricular pacing, 1-16, 1-39
blastomycosis, 6-4
body surface area, 11-9
Boerhaave syndrome, 1-3
bone infections, 6-8
bone marrow transplantation, 5-26
bradycardia, 1-32
breast cancer, 5-30
Brockenbrough sign, 1-18
bronchiectasis, 2-8
bronchitis, chronic, 2-5
Brudzinski’s sign, 6-9
Brugada syndrome, 1-34
B-type natriuretic peptide, 1-14, 2-1
Budd-Chiari syndrome, 3-25
bundle branch blocks, 1-1
burr cells, 11-7
C
calciphylaxis, 4-14
calcium disorders, 7-11
calcium pyrophosphate dehydrate deposition disease, 8-6
Cameron’s lesions, 3-4
cancer of unknown primary site, 5-37
Candida species, 6-3
carbon monoxide poisoning, 2-18
carcinoid, 3-6
cardiac resynchronization therapy, 1-16, 1-39
cardiac shunt, 11-5
cardiomyopathy, 1-17
dilated, 1-17
hypertrophic, 1-18
peripartum, 1-17
restrictive, 1-19
vs. constrictive pericarditis, 1-19
Takotsubo, 1-17
cardiorenal syndrome, 4-13
carotid revascularization, 9-7
cat scratch disease, 6-6
cauda equina syndrome, 9-11
celiac disease, 3-7
cellulitis, 6-6
central venous catheter-related
blood streams infections, 6-12
cerebrovascular disease, 9-6
Chagas, 1-17
Charcot’s triad, 3-28
Chediak-Higashi syndrome, 5-9
chemotherapy side effects, 5-37
chest pain, 1-3
chest tubes, 10-2
Child-Turcotte-Pugh scoring system, 11-7
chimeric antigen receptor (CAR)-T cells, 5-37
cholangitis, 3-28
cholecystitis, 3-27
choledocholithiasis, 3-28
cholelithiasis, 3-27
cholera, 3-5
cholestasis, 3-16
cholesterol emboli syndrome, 1-5
chronic kidney disease, 4-13
chronic obstructive pulmonary disease (COPD), 2-5, P-1
Churg-Strauss syndrome, 8-19
as cause of asthma, 2-2
as cause of glomerulonephritis, 4-17
as cause of interstitial lung disease, 2-10
Chvostek’s sign, 7-12
cirrhosis, 3-21
claudication, neurogenic vs. vascular, 9-12
clinical institute withdrawal assessment for alcohol (CIWA-Ar), 11-9
clostridial myonecrosis, 6-7
Clostridium difficile infection, 3-6
coagulation cascade, 5-6
coagulopathies, 5-10
coarctation of aorta, 1-28
coccidioidomycosis, 6-3
cold caloric, 9-1
colonic polyps, 3-9
colonic pseudo-obstruction, 3-8
colonoscopy, screening, 5-33
colorectal cancer (CRC), 5-33
coma, 9-1
compartment syndrome, 10-2
confusion, 9-1
connective tissue diseases, 8-11
Conn’s syndrome, 7-8
constipation, 3-8
constrictive pericarditis, 1-27
continuous positive airway pressure (CPAP), 2-19, 2-20
continuous veno-venous hemofiltration, 4-16
contrast-induced acute kidney injury, 4-13
conus medullaris syndrome, 9-11
coronary angiography, 1-5, P-13
computed tomographic, 1-4
coronary arteries, P-13
coronary artery bypass grafting (CABG), 1-5
coronary artery calcium score, 1-4
coronary revascularization, 1-5
Courvoisier’s sign, 5-34
creatinine clearance, 11-7
CREST syndrome, 8-12
Crohn’s disease, 3-10
cryoglobulinemia, 8-21
Cryptococcus, 6-3
cryptogenic organizing pneumonia, 2-10
crystal deposition arthritides, 8-5
Cullen’s sign, 3-13
Cushing’s reflex, 3-20
Cushing’s syndrome, 7-7
cutaneous leukocytoclastic angiitis, 8-20
cyanide poisoning, 2-18
cyanosis, 2-18
cystic fibrosis, 2-8
cystitis, 6-5
cytomegalovirus, 6-19
D
dactylitis, 8-7
decubitus ulcer, 10-2
deep venous thrombosis, 2-13
delirium, 9-1
delirium tremens, 9-5
dementia, 9-1
dengue, 6-23
dermatomyositis, 8-12
desquamative interstitial pneumonia, 2-10
diabetes mellitus, 7-13
diabetic foot, 6-7
diabetic ketoacidosis (DKA), 7-14
dialysis, 4-15
diarrhea, 3-5
Dieulafoy’s lesion, 3-4
diffuse alveolar damage, 2-22
diffuse alveolar hemorrhage, 2-10, 5-27
diplopia, 10-4
direct oral anticoagulants (DOACs), 5-10
disc herniation, 9-12
discriminant function, 3-19
disseminated gonococcal arthritis, 8-10
disseminated intravascular coagulation (DIC), 5-10
diuresis, 4-15
diverticular disease, 3-9
dizziness, 9-5
doll’s eyes, 9-1
Dressler’s syndrome, 1-11, 1-25
Duke treadmill score, 1-4
duodenal ulcer, 3-2
dyslipidemias, 7-16
dysphagia, 3-1
dyspnea, 2-1
dysuria, 6-5
E
Eaton-Lambert syndrome, 5-28, 9-9
echocardiography, P-9
Ehlers-Danlos syndrome, 1-30, 1-31
ehrlichiosis, 6-21
electrocardiography, 1-1
emphysema, 2-5
encephalitis, viral, 6-11
endocarditis, 6-12
endomyocardial fibrosis, 1-19
enthesitis, 8-7
eosinophilia, 5-12
eosinophilic granulomatosis with polyangiitis, 8-19
as cause of asthma, 2-2
as cause of glomerulonephritis, 4-17
as cause of interstitial lung disease, 2-10
eosinophilic pneumonias, 2-10
epidural abscess, 6-8
epidural hematoma, 9-7
epilepsy, 9-3
erosive gastropathy, 3-3
erysipelas, 6-6
erythema migrans, 6-20
erythema multiforme, 6-22
erythema nodosum, 2-9, 6-23, 8-8, 8-20
erythrocyte sedimentation rate, 8-2
erythromelalgia, 5-15
esophageal reflux, 3-1
esophageal ring, 3-1
esophageal spasm, 1-3
esophageal web, 3-1
essential thrombocythemia, 5-15
ethylene glycol intoxication, 4-2
exercise tolerance test, 1-4
F
factor V Leiden, 5-11
familial adenomatous polyposis, 5-33
familial hypocalciuric hypercalcemia, 7-11
familial Mediterranean fever, 6-22
Fanconi’s syndrome, 4-3
Felty’s syndrome, 8-3
fever
neutropenia and, 5-35
Pel-Ebstein, 5-23
syndromes, 6-22
fibromyalgia, 8-13
Fitz-Hugh-Curtis syndrome, 8-10
focal segmental glomerulosclerosis, 4-18
folate deficiency, 5-3
folliculitis, 6-6
food poisoning, 3-5
Fournier’s gangrene, 6-7
fractional excretion of Na, 4-12, 11-7
fractional flow reserve (FFR), 1-5
fungal infections, 6-3
G
Gaisböck’s syndrome, 5-15
Gallavardin effect, 1-20
gallstone, 3-13
gallstone ileus, 3-27
gas gangrene, 6-7
gastric antral vascular ectasia, 3-4
gastric ulcer, 3-2
gastroesophageal reflux disease (GERD), 3-1
gastrointestinal bleeding, 3-3
gastroparesis, 3-8
gastrostomy tubes, 10-2
giant cell arteritis, 8-17
Gitelman’s syndrome, 4-5, 4-10, 7-8
Glanzmann’s thromboasthenia, 5-9
Glasgow Coma Scale, 9-1
glaucoma, 10-4
glomerulonephritis, 4-17
glucose-6-phosphate dehydrogenase (G6PD) deficiency, 5-4
glycemic control, in critical care, 2-23
Goodpasture’s syndrome
as cause of alveolar hemorrhage, 2-10
as cause of glomerulonephritis, 4-17
Gottron’s papules, 8-13
gout, 8-5
graft-versus-host disease (GVHD), 5-26, 5-27
granulomatosis with polyangiitis, 8-18
as cause of glomerulonephritis, 4-17
as cause of interstitial lung disease, 2-10
Graves’ disease, 7-5
Grey Turner’s sign, 3-13
Guillain-Barré syndrome, 9-8
H
Hamman-Rich syndrome, 2-10
Hashimoto’s thyroiditis, 7-3
headache, 9-10
heart failure, 1-14
with preserved EF, 1-16
Helicobacter pylori infection, 3-2
heliotrope rash, 8-13
hematemesis, 3-3
hematochezia, 3-3
hematopoietic stem cell transplantation, 5-26
hematuria, 4-20
hemochromatosis
as cause of cirrhosis, 3-23
as cause of DCM, 1-17
as cause of RCM, 1-19
hemodialysis, 4-15
hemolytic-uremic syndrome, 5-9
hemophilia, 5-10
hemoptysis, 2-7
hemostasis disorders, 5-6
Henoch-Schönlein purpura, 8-19
as cause of glomerulonephritis, 4-17
heparin-induced thrombocytopenia, 5-8
heparin nomograms, 11-8
hepatic encephalopathy, 3-22
hepatic hydrothorax, 2-12, 3-22
hepatitis, 3-17
alcoholic, 3-19
autoimmune, 3-19
ischemic, 3-19
viral, 3-17
hepatocellular carcinoma, 3-23, 5-35
hepatopulmonary syndrome, 3-23
hepatorenal syndrome, 3-22
hereditary nonpolyposis colorectal cancer, 5-33
hereditary spherocytosis, 5-5
Hermansky-Pudlak syndrome, 5-9
herpes zoster, 6-11
histoplasmosis, 6-3
Howell-Jolly bodies, 5-5, 11-8
human immunodeficiency virus (HIV), 6-17
hyperaldosteronism, 7-8
as cause of hypokalemia, 4-10
as cause of metabolic alkalosis, 4-4
hyperbilirubinemia, 3-15
hypercalcemia, 7-11
hypercapnia, 2-18
hypercholesterolemia, 7-16
hypercoagulable states, 5-11
hypercortisolism, 7-7
hyperhomocysteinemia, 5-11
hyperkalemia, 4-11
hypernatremia, 4-8
hyperosmolar hyperglycemic state, 7-15
hyperparathyroidism, 7-11
secondary, 4-14
hyperpituitary syndrome, 7-2
hyperprolactinemia, 7-2
hypersensitivity pneumonitis, 2-10
hypersensitivity vasculitis, 8-20
hypersplenism, 5-5
hypertension, 1-28
hypertensive crisis, 1-29
hyperthyroidism, 7-4
hypertriglyceridemia, 7-16
hypertrophic pulmonary
osteoarthropathy, 5-28
hypoaldosteronism, 7-9
as cause of hyperkalemia, 4-11
as cause of metabolic acidosis, 4-3
hypocalcemia, 7-12
hypoglycemia, 7-15
hypokalemia, 4-10
hypomagnesemia, 4-11
hyponatremia, 4-6
hypoparathyroidism, 7-12
hypopituitary syndromes, 7-1
hypothermia, induced, 9-2
hypothyroidism, 7-3
hypoxemia, 2-18
I
ICU medications, 11-1
ideal body weight, 11-9
idiopathic interstitial pneumonia, 2-10
idiopathic pulmonary fibrosis, 2-10
IgA nephropathy, 4-18
IgG4-related disease, 8-20
immune checkpoint inhibitors, 5-37
immune thrombocytopenic purpura, 5-7
immunotherapy side effects, 5-37
impetigo, 6-6
implantable cardiac defibrillator, 1-16, 1-39
infections in susceptible hosts, 6-4
inflammatory bowel disease, 3-10
inflammatory markers, 8-2
influenza, 6-2
instantaneous wave-free ratio (iFR), 1-5
interstitial lung disease, 2-9
intestinal ischemia, 3-12
intracranial hemorrhage (ICH), 9-7
intraductal papillary mucinous neoplasm, 5-34
intramural hematoma (aortic), 1-31
iron deficiency, 5-1
irritable bowel syndrome (IBS), 3-7, 3-8
ischemic colitis, 3-12
isopropyl alcohol intoxication, 4-3
J
Janeway lesions, 6-13
jaundice, 3-15
Jod-Basedow effect, 7-6
joint fluid, analysis, 8-1
K
Kaposi’s sarcoma, 6-19
Kernig’s sign, 6-9
ketoacidosis, 4-2
kidney transplantation, 4-16
koilonychia, 5-1
Kussmaul’s sign, 1-27
L
lactic acidosis, 4-2
lactose intolerance, 3-6
Lady Windermere syndrome, 2-8
Langerhans cell granulomatosis, 2-10
left ventricular hypertrophy, 1-1
left ventricular noncompaction, 1-17
left ventricular thrombus, 1-11
acute lymphoblastic, 5-18
acute myelogenous, 5-17
acute promyelocytic, 5-18
chronic lymphocytic, 5-23
chronic myelogenous, 5-19
hairy cell, 5-21
leukostasis, 5-17
Libman-Sacks endocarditis, 8-15
Liddle’s syndrome, 4-5, 4-10, 7-8
Light’s criteria, 2-11
limb ischemia, acute, 1-41, 10-1
lipodystrophy, 6-18
liver failure, 3-20
liver tests, abnormal, 3-15
liver transplantation, 3-23
Loeys-Dietz syndrome, 1-30, 1-31
Löffler’s endocarditis, 1-19
Löffler’s syndrome, 2-10
Löfgren’s syndrome, 2-9
lung cancer, 5-28
lung transplantation, 2-24
lupus anticoagulant, 5-11
lupus pernio, 2-9
Lyme disease, 6-20
lymphadenopathy, 5-12
lymphangioleiomyomatosis, 2-10
lymphocytic interstitial pneumonia, 2-10
lymphocytosis, 5-12
lymphoma, 5-20
CNS, 6-19
Hodgkin, 5-20
non-Hodgkin, 5-21
small lymphocytic, 5-23
M
macro-ovalocytes, 5-3
malabsorption, 3-7
malaria, 6-23
mammography, 5-30
mechanical circulatory support, 1-15
mechanical ventilation, 2-19
mechanic’s hands, 8-13
Meckel’s diverticulum, 3-4
MELD score, 3-21
melena, 3-3
membranoproliferative glomerulonephritis, 4-18
membranous nephropathy, 4-18
Meniere’s disease, 9-5
meningitis
acute bacterial, 6-9
aseptic, 6-10
mental status, change in, 9-1
mesenteric ischemia, acute, 3-12
metabolic acidosis, 4-2
metabolic alkalosis, 4-4
metabolic syndrome, 7-16
methanol intoxication, 4-2
methemoglobinemia, 2-18
microscopic colitis, 3-7
microscopic polyangiitis, 8-19
as cause of glomerulonephritis, 4-17
as cause of interstitial lung disease, 2-10
migraine headache, 9-10
milk-alkali syndrome, 7-11
minimal change disease, 4-18
Mirizzi syndrome, 3-27
mitral regurgitation, 1-22
mitral stenosis, 1-23
mitral valve prolapse, 1-23
mixed connective tissue disease (MCTD), 8-14
molluscum contagiosum, 6-18
monoclonal gammopathy of uncertain significance, 5-25
monocytosis, 5-12
mucinous cystic neoplasm of pancreas, 5-34
Mucor infection, 6-4
multiple endocrine neoplasia (MEN) syndromes, 7-2
multiple myeloma, 5-24
murmurs, eponymous
Austin Flint, 1-21
Murphy’s sign, 3-27
myalgias, 8-13
myasthenia gravis, 9-9
Mycobacterium avium complex, disseminated, 6-19
mycosis fungoides, 5-21
myelodysplastic syndromes, 5-14
myelofibrosis, primary, 5-16
myeloid neoplasms, 5-14
myeloproliferative neoplasms, 5-15
myocardial infarction (MI)
non-ST elevation, 1-7
ST elevation, 1-9
myocardial viability, 1-4
myositis, 8-12
myxedema, 7-4
N
necrotizing fasciitis, 6-7
nephrogenic systemic fibrosis, 4-13
nephrolithiasis, 4-20
nephrotic syndrome, 4-18
nerve root compression, 9-11
neuropathies, 9-8
neutropenic enterocolitis, 5-35
neutrophilia, 5-12
New York Heart Association
classification, 1-14
nonalcoholic fatty liver disease (NAFLD), 3-19
noninvasive ventilation, 2-19
non-TB mycobacterium, 2-8
nonspecific interstitial pneumonia, 2-10
nutrition, in hospitalized Pt, 3-8
O
ocular motor palsies, 10-4
oculocephalic maneuver, 9-1
Ogilvie’s syndrome, 3-8
optic neuritis, 10-4
optic neuropathy, ischemic, 10-4
oral hairy leukoplakia, 6-18
orbital cellulitis, 10-4
orthostatic hypotension, 1-37
Osler’s nodes, 6-13
osteoarthritis, 8-1
osteomyelitis, 6-8
P
pacemakers, 1-39
Paget’s disease
of bone, 7-11
of breast, 5-30
Pancoast’s syndrome, 5-28
pancreatic cancer, 5-34
pancreatic insufficiency, 3-7
pancreatitis, 3-13
pancytopenia, 5-3
panhypopituitarism, 7-1
papillary muscle rupture, 1-10
Pappenheimer bodies, 5-2
paroxysmal nocturnal hemoglobinuria, 5-4
patent foramen ovale, 9-7
peptic ulcer disease (PUD), 1-3, 3-2, 3-3
percutaneous coronary intervention (PCI), 1-5
pericardial effusion, 1-25
pericardial tamponade, 1-26
pericarditis, 1-25
periodic paralysis
hyperkalemic, 4-11
hypokalemic, 4-10
peripheral arterial disease, 1-41
peripheral smear, findings in, 11-7
peritoneal dialysis, 4-16
peritonitis, 3-26
petechiae, 5-6
pheochromocytoma, 7-10
phlegmasia cerulea dolens, 2-13
pica, 5-1
pituitary disorders, 7-1
pituitary tumors, 7-1
plasma cell dyscrasias, 5-24
platelet disorders, 5-7
pleuritis, 1-3
Plummer-Vinson syndrome, 5-1
pneumoconioses, 2-10
Pneumocystis jiroveci pneumonia, 6-19
pneumothorax, P-4
POEMS syndrome, 5-24
polyarteritis nodosa, 8-18
polycystic kidney disease, 4-13
polycythemia vera, 5-15
polydipsia, 4-9
polymyalgia rheumatica, 8-13, 8-18
polymyositis, 8-12
polyuria, 4-9
porphyria cutanea tarda, 3-18
portal hypertension, 3-21, 3-26
portal vein thrombosis (PVT), 3-25
portopulmonary hypertension, 2-16, 3-23
preexcitation, 1-33
pregnancy, ectopic, 10-3
preoperative risk assessment, 1-40
prerenal azotemia, 4-12
primary biliary cholangitis, 3-24
primary sclerosing cholangitis, 3-24
Prinzmetal’s angina, 1-6
progressive multifocal leukoencephalopathy, 6-19
propofol infusion syndrome, 2-21
propylene glycol intoxication, 4-2
prostate cancer, 5-32
prostate-specific antigen (PSA) testing, 5-32
prostatitis, 6-5
prosthetic heart valves, 1-24
proteinuria, 4-19
prothrombin mutation, 5-11
pseudogout, 8-6
pseudo-hypoparathyroidism, 7-12
pseudo-Pelger-Huët cells, 5-14, 11-8
pseudotumor cerebri, 9-10
pulmonary alveolar proteinosis, 2-10
pulmonary artery catheter, 1-12, 11-5
pulmonary edema
CXR pattern in, P-2
pulmonary fibrosis, idiopathic, 2-10, P-6
pulmonary function tests, 2-1
pulmonary hypertension, 2-16
pulmonary infiltrates with eosinophilia, 2-10
pulsus paradoxus, 1-26
pure red cell aplasia, 5-2
purified protein derivative (PPD) test, 6-15
purpura, 5-6
pyelonephritis, 6-5
pyoderma gangrenosum, 3-10, 8-8
Q
QT interval, 1-1
R
radiculopathies, 9-11
radioactive iodine uptake scan, 7-3
Raynaud’s phenomenon, 8-14
red eye, 10-4
Reed-Sternberg cells, 5-20
refeeding syndrome, 3-8
Reiter’s syndrome, 8-7
relapsing polychondritis, 8-4
renal abscess, 6-5
renal artery stenosis, 1-28
renal failure, 4-12
renal osteodystrophy, 7-12
renal replacement therapy, 4-15
renal tubular acidosis, 4-3
respiratory acidosis, 4-5
respiratory alkalosis, 4-5
respiratory bronchiolitis-associated interstitial lung disease, 2-10
respiratory failure, 2-18
reticulocyte index, 5-1
Reynolds’ pentad, 3-28
rhabdomyolysis, 4-13
rheumatoid factor, 8-3
Rhizopus infection, 6-4
Richter’s syndrome, 5-23
Rocky Mountain spotted tick fever (RMSF), 6-21
Roth spots, 6-13
S
salicylate intoxication, 4-2
Samter’s syndrome, 2-2
cardiac manifestations of, 1-19
sciatica, 9-11
scleroderma, 8-11
seizures, 9-3
sepsis, 2-23
Sequential Organ Failure Assessment (SOFA), 2-23
seronegative spondyloarthritis, 8-7
serum-ascites albumin gradient, 3-26
Sézary syndrome, 5-21
Sheehan’s syndrome, 7-1
cardiogenic, 1-13
septic, 2-23
sicca syndrome, 8-13
sick euthyroid syndrome, 7-5
sick sinus syndrome, 1-32
silicosis, 2-10
sinusoidal obstruction syndrome, 3-25, 5-26
Sjögren’s syndrome, 8-13
small intestinal bacterial overgrowth, 3-7
smudge cells, 5-23
soft tissue infections, 6-6
solitary pulmonary nodule, 2-7
spinal cord compression, 5-36, 9-11
spinal stenosis, 9-12
splenic vein thrombosis, 3-25
splenomegaly, 5-5
spontaneous bacterial peritonitis, 3-26
treatment of in cirrhosis, 3-22
statistics, 11-9
status epilepticus, 9-4
ST depression, 1-2
ST elevation, 1-2
stent thrombosis, 1-5
steroids, in critical care, 2-23
Still’s disease, adult onset, 6-22, 8-4
stool osmotic gap, 3-7
stress test, 1-4
stroke, 9-6
struma ovarii, 7-4
subarachnoid hemorrhage, 9-7
subdural hematoma, 9-7
superior vena cava syndrome, 5-28
syncope, 1-37
syndrome of inappropriate antidiuretic hormone (SIADH), 4-7
systemic lupus erythematosus (SLE), 8-15
systemic sclerosis, 8-11
T
tachycardias, 1-32
atrial, 1-32
atrioventricular reciprocating, 1-32, 1-34
AV nodal reentrant tach, 1-32
multifocal atrial, 1-32
nonparoxysmal junctional, 1-32
sinus, 1-32
supraventricular, 1-32
ventricular, 1-34
wide-complex, 1-34
Takayasu’s arteritis, 8-17
target cells, 11-7
targeted temperature management, 9-2
temporal arteritis, 8-17
thalassemias, 5-2
thrombocytopenia, 5-7
thrombotic microangiopathies, 5-9
thrombotic thrombocytopenic purpura, 5-9
thrush, 6-18
thyroid disorders, 7-3
thyroid function tests, 7-3
thyroid cancer, 7-6
thyroid nodules, 7-6
thyroid storm, 7-5
TIMI risk score for UA/NSTEMI, 1-8
Todd’s paralysis, 9-3
torsades de pointes, 1-34
total body water, 11-7
toxic shock syndrome, 6-6
toxicology, 2-24
toxoplasmosis, 6-19
tracheostomy, 10-2
transfusion-related acute lung injury, 2-22, 5-13
transfusion therapy, 5-13
transient ischemic attack (TIA), 9-6
trans-tubular potassium gradient, 4-10, 11-7
tricuspid regurgitation, 1-24
triglycerides, 7-16
Trousseau’s
sign of hypocalcemia, 7-12
syndrome of malignancy, 5-34
tuberculosis, 6-15
tularemia, 6-21
tumor lysis syndrome, 5-36
T wave inversion, 1-2
typhlitis, 5-35
typhoid fever, 6-23
U
ulcerative colitis, 3-10
ulcers, 3-2
unstable angina, 1-7
uremia, 4-14
uremic bleeding, 5-9
urethritis, 6-5
urinalysis, 4-19
urinary tract infection (UTI), 6-5
urine anion gap, 4-3
urine osmolality, 4-6
usual interstitial pneumonia, 2-10
uveitis, 8-7
V
vaginal bleeding, 10-3
vaginal discharge, 10-3
vasculitis, 8-17
veno-occlusive disease
pulmonary, 2-16
venous thromboembolism, 2-13
ventricular aneurysm, 1-11
ventricular pseudoaneurysm, 1-11
ventricular septal defect, 1-10
Verner-Morrison syndrome, 3-6
vertigo, 9-5
vestibular caloric stimulation, 9-1
Virchow’s node, 5-34
visual changes, 10-4
visual field defect, 10-4
vitamin B12 deficiency, 5-3
vitamin D deficiency, 7-12
vitamin K deficiency, 5-10
von Willebrand’s disease, 5-9
V/Q mismatch, 2-18
W
Waldenström’s macroglobulinemia, 5-25
warfarin loading nomogram, 11-8
warfarin overdose, 5-10
Wegener’s granulomatosis, 8-18
as cause of glomerulonephritis, 4-17
as cause of interstitial lung disease, 2-10
Wernicke’s encephalopathy, 9-5
Whipple’s disease, 3-7
Wilson disease, 3-24
Wolff-Chaikoff effect, 7-6
Wolff-Parkinson-White syndrome, 1-33
X
xanthelasma, 7-16
xanthomas, 7-16
Y
yellow-nail syndrome, 2-11
Z
Zenker’s diverticulum, 3-1
Zollinger-Ellison syndrome, 3-2, 3-6
zoster, 6-11
zygomycetes, 6-4